Defining Progression in Metastatic Kidney Cancer
3 Vues
• 06/26/23
0
0
Intégrer
administrator
Les abonnés
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires